- 询价
- 辰辉创聚生物
- 中国
- NBAB-137706
- 2025年07月16日
- IHC, WB
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human Glycine receptor protein
- 形态：
液体
- 保存条件：
Short term 4℃; Long term -20℃.
- 克隆性：
单克隆
- 保质期：
见COA
- 库存：
大量
- 供应商：
辰辉创聚生物
- 应用范围：
IHC, WB
- 靶点：
Glycine receptor
- 抗体英文名：
Anti-Glycine receptor Monoclonal Antibody
- 抗体名：
Glycine receptor抗体
- 规格：
100ul; 500ul; 1ml
| 产品信息
品名:NebuSelect™ Anti-Glycine receptor Monoclonal Antibody
货号:NBAB-137706
品牌:Nebulabio
规格:100ul; 500ul; 1ml
| 产品描述
| 产品属性
Product Category：Guinea pig MAb
Reactivity：Human, Mouse, Rat, Pig, Zebrafish
Specificity：Human Glycine receptor
Immunogen：Recombinant Human Glycine receptor protein
Isotype：Monoclonal Guinea pig IgG
Purification：Protein A & Protein G Affinity Purification
Buffer：0.2 μm filtered solution in PBS, pH7.4, containing 0.09% Sodium azide, 50% glycerol.
Conjugate：Unconjugated
Applications：IHC, WB
Dilution：IHC 1:50～1:500; WB 1:1000～1:5000
Storage：Store at 4°C for short-term, -20°C for long-term. Avoid repeated freezing and thawing cycles.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Aspects of CNS Lupus: Mouse Models of Anti-NMDA Receptor Antibody Mediated Reactivity
concepts of these models and provide protocols for the following: (1) the induction of anti-dsDNA, anti-NMDAR antibodies, (2) testing serum antibody titer by ELISA, (3) breaching blood brain barrier (BBB) integrity with LPS and epinephrine, (4) passive
Radioligand Binding Assays for the Glycine Site on N‐Methyl‐D‐Aspartate Receptors
a competitive binding assay for the glycine binding site on the NMDA subtype of glutamate receptors in rat brain homogenates. Agonists of the NMDA receptor associated glycine binding site have been proposed as potential therapeutics in cognitive disorders
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
